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Abstract
Antibiotic chemotherapy effectively cures many infections caused by
susceptible bacterial pathogens. However, in some cases, even extended
treatment duration does not completely eradicate the pathogenic bacteria
from host tissues. A common model for underlying mechanisms assumes
the stochastic formation of bacterial persisters similar to observations in
laboratory cultures. However, alternative explanations related to the
complexity of infected host tissues could also be relevant. We discuss
several of these aspects and emphasize the need for integrated analysis as
a basis for new control strategies.
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Antibiotics have been saving the lives of millions of people. 
For most bacterial pathogens, short-term treatments of a 
few days effectively cure infections and prevent relapses1,2. 
However, in some cases such as tuberculosis and other chronic 
infections such as deep-seated abscesses with Staphylococ-
cus aureus, severe typhoid fever, or polymicrobial infections of 
patients with cystic fibrosis, extended treatments over months 
and even years can fail to completely eradicate the patho-
gens from tissues, posing a risk for relapse (Figure 1A). Many 
treatment failures are due to inheritable antibiotic resistance. 
However, surprisingly, treatment failures also occur when 
the pathogen retains full susceptibility to the antibiotics of 
choice in laboratory tests. There is an urgent medical need 
to improve the efficacy and shorten the treatments for these 
patients on the basis of a detailed mechanistic understanding 
of the problem. Several different factors influence antibiotic 
activities against pathogenic bacteria in host tissues. Most 
research groups active in the field focus on one particular 
factor: the stochastic variation of pathogen cells. However, other 
factors could be at least as important. In this review, we discuss 
some of these aspects and stress the need for an integrated 
analysis (Figure 1B).
Stochastic variation of bacterial properties in 
laboratory cultures
Bacterial cultures show heterogeneous properties even under 
completely homogeneous laboratory conditions indicating 
important endogenous stochastic variation within bacterial 
cells3–5. Exposure of bacterial cultures to lethal concentrations 
of bactericidal antibiotics rapidly kills most bacterial cells, 
but a small fraction of cells can survive for extended periods. It 
is possible that similar processes occur also in infected host tis-
sues where they could contribute to incomplete eradication under 
antimicrobial chemotherapy. Because this phenomenon is 
readily observable in vitro, it has attracted the attention of a 
large number of research groups.
In many cases, the surviving small subset of bacteria repre-
sents non-growing remnant cells of a previous stationary cul-
ture that have an extended lag phase6. Such persisters are thus 
one particular instance of the widely characterized exten-
sive heterogeneity of stationary-phase cultures7. A variety of 
other stress conditions also lead to increased antibiotic toler-
ance, including low ATP levels8, over-expression of toxins or 
unrelated proteins9, translation arrest10,11, oxidative stress12, 
and pre-exposure of cells to sub-MIC levels of bactericidal 
antibiotics13. Importantly, even growing bacteria show widely het-
erogeneous kill rates indicating that dormancy is not absolutely 
required for survival during antibiotic exposure14–17, implying 
alternative mechanisms leading to heterogeneous killing rates in 
clonal populations. These include asymmetric cell division4,18,19 
with uneven partitioning of efflux pumps among daughter cells20, 
heterogeneous expression of prodrug-activating enzymes14, 
transient gene amplifications21, and heterogeneous induction 
of specific stress responses17.
Although endogenous stochastic variation in bacteria often 
is assumed to play a major role in impairing antibiotic effi-
cacy, empirical evidence is surprisingly scarce in infected 
tissues22. Some clinical isolates of Pseudomonas aeruginosa 
and Escherichia coli from antibiotic-treated patients showed 
increased persister frequencies23,24, but this could also reflect 
fitness advantages of persisters under hostile host condi-
tions or phage attacks. One argument against a general clinical 
relevance of persisters is the effectiveness of short-term anti-
biotic chemotherapy against many pathogens, which readily 
form refractory persisters in laboratory cultures1,2. Persisters 
thus might arise in patients but the host immune system seems 
to be capable of eradicating them quickly22. Moreover, bacte-
riostatic antibiotics, which cause population-wide growth arrest 
in bacteria and make them tolerant against other antibiotics, 
are as effective as bactericidal antibiotics for the treatment of 
most infectious diseases25. However, the distinction between 
Figure 1. Treatment failures and potential causes. (A) Incomplete eradication of bacterial pathogens during extended antimicrobial 
chemotherapy causes a risk for relapses after termination of therapy. (B) Possible mechanisms that enable a bacterial subset (red) to survive 
during treatment while the rest of the bacterial population (blue) is successfully eradicated.
Page 3 of 7
F1000Research 2019, 8(F1000 Faculty Rev):1781 Last updated: 21 OCT 2019
bacteriostatic and bactericidal antibiotics is not absolute, as many 
“bacteriostatic” drugs can kill bacteria at higher exposure levels 
or during extended exposure times or both25. In addition, trans-
lation arrest by bacteriostatic antibiotics might impair survival 
in host tissues due to an inability to produce essential virulence 
factors or stress defenses. Finally, non-growing persisters can 
also occur in biofilms where they could escape clearance by 
host phagocytes26.
Although the general relevance of bacterial persisters in 
infectious diseases remains unclear27, they might be crucial for 
infections with frequent relapses even after extended treatment 
durations28,29. However, other much less studied mechanisms 
could also contribute to infection relapse.
Pathogen physiology in host tissues
Clinical microbiology relies largely on standard in vitro assays 
in rich media to assess antibiotic susceptibility of patho-
gens. The results often are predictive of therapeutic efficacy, 
but pathogen physiology is significantly different under assay 
conditions compared with infected host tissues30. Genetic 
screens in diverse pathogens typically have revealed many hun-
dreds of virulence genes that are specifically required in host 
tissues but not in rich broth cultures, indicating large-scale 
relevant functional differences. Several parameters that dif-
fer between tissues and broth cultures also have a major impact 
on antibiotic activities. This includes31 oxygen tension32, carbon 
dioxide tension33,34, metabolite concentrations35, pH36,37, and anti-
microbial effector molecules of the host immune system such as 
cationic antimicrobial peptides (CAMPs)38 and nitric oxide39. 
Limited nutrient supply and stress conditions can result in 
slow pathogen proliferation, which strongly affects the activity 
of most antibiotics40–42. Finally, pathogens can also adapt to 
the antibiotic exposure43 and this adaptation might be more 
successful when antibiotics gradually penetrate into the 
infection site, compared with abrupt exposure in standard 
in vitro assays. All of these effects might lead to poor 
antibiotic efficacy, requiring extended treatment times.
Pathogen heterogeneity in host tissues
As an additional complexity, pathogens show significantly 
increased single-cell heterogeneity in tissues and body fluids 
of human patients and infected animals, compared with homo-
geneous laboratory cultures3,44–46. This includes wide variation 
in bacterial growth rates, aggregation state, drug-efflux pumps, 
metabolism, and stress responses. All of these parameters influ-
ence the activity of antimicrobials, and it is possible that patho-
gen subsets with favorable properties tolerate antimicrobial 
exposure much better than their conspecifics, making eradi-
cation more difficult. Host-induced pathogen heterogeneity 
can reflect inhomogeneous host microenvironments triggering 
differences in bacterial physiology45–47 but also host-induced 
pathogen activities that change local microenvironments48.
An astonishing early finding was the differential recovery of 
Mycobacterium tuberculosis from open and closed (that is, 
no connection to airways) cavities in the lung of patients with 
tuberculosis49. Whereas drug-resistant M. tuberculosis recov-
ered from open cavities formed visible colonies on plates within 
a few weeks, M. tuberculosis from closed cavities of the same 
patients appeared only after a lag of many months. Strikingly, 
these colonies showed full drug susceptibility, suggesting limited 
selection for resistance development despite extended anti-
microbial treatment. Sputum of patients with tuberculosis 
also contains mycobacteria with a wide range of cultivation 
phenotypes50. A recent example that directly reveals heteroge-
neous bacteria physiology in tissues comes from Salmonella 
mouse infection models. Salmonella shows local and transient 
adaptations to divergent nutrient supply and disparate antimi-
crobial host attacks with reactive oxygen and nitrogen species51. 
The resulting heterogeneity in Salmonella growth rates has a 
major impact on Salmonella eradication52–54.
Drug concentration at the site of infection
Antimicrobials must reach bacterial cells to execute their bac-
tericidal/bacteriostatic activities. Bacterial subsets hiding in 
tissue microenvironments with poor drug penetration might 
delay complete eradication during antimicrobial chemotherapy. 
Indeed, host anatomy and biochemistry might provide physi-
cal or chemical barriers (or both) for drug penetration. This 
includes the blood–brain barrier, bones, and serum proteins 
that bind antimicrobials, thereby decreasing their free concen-
tration. Host inflammation increases tissue heterogeneity by 
altering endothelial permeability and the formation of lesions 
and abscesses. On the other hand, certain drugs such as fluo-
roquinolones, azithromycin, and bedaquiline accumulate in host 
phagocytes55–57, which might lead to elevated drug concentra-
tions around the bacteria. Antimicrobial availability at the site of 
infection depends on the intestinal absorption of orally adminis-
tered drugs, the distribution to the infected tissue, metabolism, and 
excretion. All of these processes depend on the physicochemical 
properties of the drug as well as the physiology of the patient, 
which might vary during bacterial infection. Drug penetration 
into accessible tissues can be measured by using microdialysis58, 
but analysis of body fluids such as serum, cerebrospinal fluid, 
tracheal secretions, or urine is more common. It is unclear how 
representative these values are for drug availability around 
the bacterial cells during infection. Indeed, novel methods 
such as matrix-assisted laser desorption/ionization (MALDI) 
mass spectrometry imaging demonstrate remarkable differences 
in local drug concentrations in lesions compared with sur-
rounding lung tissue in tuberculosis patients and animals 
infected with M. tuberculosis59,60. The emerging data suggest 
that inhomogeneous drug exposure could be a crucial factor 
for difficulties in eradicating M. tuberculosis. Unfortunately, 
experimental data are lacking for most other infectious 
diseases.
Conclusions
Antibiotic chemotherapy of most bacterial infections is highly 
effective if the causative pathogen is susceptible to the anti-
biotic of choice. However, some infections require extended 
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treatments to prevent relapses. Antibiotic-tolerant bacte-
rial subsets (“persisters”) as observed in laboratory cultures 
might contribute to this problem. Alternatively, the host tissue 
environment could be decisive by providing inhomogeneous 
stress conditions and limiting drug distribution. To clarify these 
issues, we need more integrated in vivo research exploiting 
recent single-cell approaches and complementary techniques 
such as mass spectrometry imaging and three-dimensional 
high-resolution whole-organ microscopy61,62. A better under-
standing of the real problems impairing the chemotherapy of 
such infections is critically important to devise novel strategies 
for more effective and rapid treatments.
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